CNTB — Connect Biopharma Holdings Ltd
NASDAQ · Healthcare · Biotechnology
$2.52
+$0.17 (+6.99%)
Connect Biopharma Holdings Ltd (CNTB) is a biotechnology company listed on NASDAQ. It is led by Barry D. Quart Pharm.D., based in 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130, with about 62 employees. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Latest reported CNTB revenue for 2025-09-30 was $16.0K. Net income was -$17.2M. Revenue was down 66.7% from 2025-06-30 to 2025-09-30. CNTB currently screens at market cap $63.3M.
Use this CNTB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CNTB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CNTB SEC filings page. Lician reads the product cache first so this HTML stays unique to Connect Biopharma Holdings Ltd even when a live quote feed is slow.
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
CNTB Key Statistics
Market Cap
$63.34M
Volume
395,283
Previous Close
$2.45
Day Range
$2.33 – $2.50
EPS
-$0.28
Revenue
$26.03M
Net Income
-$15.63M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-60.0%
Employees
62
CNTB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $26.03M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$15.63M | -$62.11M |
| EPS (Diluted) | -$0.28 | -$1.13 |
Total Assets
$101.28M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$78.23M
Operating Cash Flow
-$23.61M
Free Cash Flow
$0.00
Connect Biopharma Holdings Ltd Company Information
- CEO & Director
- Barry D. Quart Pharm.D.
- Headquarters
- 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130
- Website
- www.connectbiopharm.com
- Phone
- 858 727 1040
- IPO / Founded
- 2021-03-19
- Sector
- Healthcare
- Industry
- Biotechnology